Buscar
Vyne Therapeutics Inc
VYNEAñadir a la lista de seguimiento
0.681USD
+0.030+4.66%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
22.71MCap. mercado
PérdidaP/E TTM
Más Datos de Vyne Therapeutics Inc Compañía
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Información de Vyne Therapeutics Inc
Símbolo de cotizaciónVYNE
Nombre de la empresaVyne Therapeutics Inc
Fecha de salida a bolsaJan 25, 2018
Director ejecutivoDomzalski (David)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 25
Dirección685 Route 202/206 N., Suite 301
CiudadBRIDGEWATER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08807
Teléfono18007757936
Sitio Webhttps://vynetherapeutics.com/
Símbolo de cotizaciónVYNE
Fecha de salida a bolsaJan 25, 2018
Director ejecutivoDomzalski (David)
Ejecutivos de Vyne Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
100.91K
-3.97%
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
62.86K
+25.14%
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
55.57K
+0.61%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Vyne Therapeutics Inc?
Los cinco principales accionistas de Vyne Therapeutics Inc son: Mr. Tyler Zeronda
¿Cuántas instituciones poseen acciones de Vyne Therapeutics Inc (VYNE)?
A fecha de 2026Q1, 92 instituciones poseen acciones de Vyne Therapeutics Inc, con un valor de mercado combinado de aproximadamente 11.08M, lo que representa el 33.26% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1672969.00.